Leerink Partners Starts Neurocrine Bio. (NBIX) at Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $164.37 +13.09%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Leerink Partners analyst Marc Goodman initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Market Perform rating and a price target of $110.00.
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $105.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
- Northland Starts Aureus Greenway Holdings (PUSA) at Outperform
- Baird Reiterates Outperform Rating on Neurocrine Bio. (NBIX)
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
